

31 October 2024

2024/25 Invitation to Tender

Pharmac's 2024/25 Invitation to Tender (2024/25 ITT) has been released today.

If you have already registered your e-mail address with Pharmac's tendering e-portal you can access the 2024/25 ITT in the e-portal in Current Tenders.

[Go to the In-Tend e-portal](#)

If you have not registered your company with the e-portal, and you would like to participate in the 2024/25 ITT, please register online.

[Register your company with the In-Tend e-portal](#)

A complete copy of the 2024/25 ITT is available on the Pharmac website. We will not be posting out any hard copies of the 2024/25 ITT.

[Find the 2024/25 ITT on our website](#)

If you wish to submit a Tender Bid in relation to community supply and/or hospital supply, you must submit it via the Electronic Portal to Pharmac no later than **4 pm (New Zealand time) on Thursday 12 December 2024**.

Changes to the 2024/25 ITT product list

Please note that the product list (Schedule Two) consulted on in July 2024 has changed. Some products have been added, removed or amended either as a result of:

- clinical advice received (e.g. from the Tender Clinical Advisory Committee); and/or
- feedback received on the draft 2024/25 ITT; and/or
- a review of unresolved bids from previous tenders.

The following items have been added to the 2024/25 ITT:

Chemical Name	Line Item
Acetic acid with hydroxyquinoline and ricinoleic acid	Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator
Alfacalcidol	Cap 0.25 mcg
Alfacalcidol	Cap 1 mcg
Alfacalcidol	Oral drops 2 mcg per ml
Amphotericin B	Liposomal inj 50 mg
Calcium Gluconate	Inj 10%
Cefalexin Monohydrate	Grans for oral liq 25 mg per ml

Chemical Name	Line Item
Cefalexin Monohydrate	Grans for oral liq 50 mg per ml
Celecoxib	Cap 100 mg
Celecoxib	Cap 200 mg
Chlorhexidine gluconate	Handrub 0.5 - 1% with ethanol 70%
Chlorhexidine gluconate	Soln 4%
Ciprofloxacin	Inj 2 mg per ml, 100 ml
Clobazam	Liq
Colestyramine	Powder for oral liq 4 g

Chemical Name	Line Item
Diclofenac sodium	Tab long-acting 75 mg
Ethinylestradiol with levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg
Ethinylestradiol with levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg
Fluticasone propionate	Metered aqueous nasal spray, 50 mcg per dose
Hydrogen Peroxide	Crn 1%
Iron (as ferric carboxymaltose)	Inj 50 mg per ml, 10 ml vial
Ivermectin	Tab 3 mg
Mirtazapine	Tab 15 mg
Mirtazapine	Tab 30 mg
Mirtazapine	Tab 45 mg
Neostigmine metisulfate with glycopyrronium bromide	Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml
Oestradiol valerate	Tab 1 mg
Oestradiol valerate	Tab 2 mg
Paracetamol	Inj 10 mg per ml, 100 ml
Paracetamol with ibuprofen	Inj 1000 mg with ibuprofen 300 mg
Potassium Chloride	Tab long-acting 600 mg
Prazosin Hydrochloride	Tab 1 mg
Prazosin Hydrochloride	Tab 2 mg
Prazosin Hydrochloride	Tab 5 mg
Preservative free Ophthalmic	Gel
Ranitidine	Tab 150 mg

Chemical Name	Line Item
Ranitidine	Tab 300 mg
Sevelamer carbonate	Tab 800 mg
Testosterone undecanoate	Inj 250 mg per ml
Thiamine Hydrochloride	Inj 100 mg per ml, 2 ml
Thiamine Hydrochloride	Inj 50 mg per ml
Varenicline (Current Access)	Tab 0.5 mg x 11 and 1 mg x 42
Varenicline (Current Access)	Tab 1 mg
Varenicline (Widened Access)	Tab 0.5 mg x 11 and 1 mg x 42
Varenicline (Widened Access)	Tab 1 mg
Vinorelbine	Cap 20 mg
Vinorelbine	Cap 30 mg
Vinorelbine	Cap 80 mg
Voriconazole	Powder for oral suspension 40 mg per ml
Voriconazole	Tab 200 mg
Voriconazole	Tab 50 mg
Water for injection	Purified for inj, 250 ml bag
Water for injection	Purified for inj, 500 ml bag
Xylometazoline	Nasal spray 0.1%
Zinc and castor oil	Crn (pack size 50 g or less)
Zinc and castor oil	Oint (pack size 50 g or less)
Zinc and castor oil	Oint BP (pack size 30 g or less)

The following items have been amended in the 2024/25 ITT:

Chemical Name	Line Item
Adrenaline autoinjector	Inj 0.15 mg per 0.3 ml
Adrenaline autoinjector	Inj 0.3 mg per 0.3 ml
Bupivacaine hydrochloride with glucose	Inj 0.5% with glucose 8%, 4 ml
Caffeine citrate	Inj 20 mg per ml (caffeine 10 mg per ml)
Capecitabine	Tab 150 mg
Capecitabine	Tab 500 mg
Cetomacrogol with glycerol	Crn 90% with glycerol 10%, 100-500 ml

Chemical Name	Line Item
Cetomacrogol with glycerol	Crn 90% with glycerol 10%, 750-1,500 ml
Chloramphenicol	Eye drops 0.5%
Clopidogrel	Tab 75 mg
Clotrimazole	Vaginal crn 1% with applicators
Clotrimazole	Vaginal crn 2% with applicators
Compound electrolytes	Powder for soln for oral use
Compound electrolytes with glucose [dextrose]	Soln with electrolytes

Chemical Name	Line Item
Cyclizine lactate	Inj 50 mg per ml, 1 ml
Dexamethasone phosphate	Inj 4 mg per ml, 1 ml
Dexamethasone phosphate	Inj 4 mg per ml, 2 ml
Droperidol	Inj 2.5 mg per ml, 1 m
Fingolimod	Cap 0.5 mg
Fludarabine phosphate	Tab 10 mg
Gefitinib	Tab 250 mg
Intra-uterine device (Non-hormonal)	IUD Long
Intra-uterine device (Non-hormonal)	IUD Medium
Intra-uterine device (Non-hormonal)	IUD Short
Methadone hydrochloride	Tab 5 mg
Methylphenidate hydrochloride (widened access)	Cap modified-release 10 mg
Methylphenidate hydrochloride (widened access)	Cap modified-release 20 mg
Methylphenidate hydrochloride (widened access)	Cap modified-release 30 mg
Methylphenidate hydrochloride (widened access)	Cap modified-release 40 mg
Methylphenidate hydrochloride (widened access)	Cap modified-release 60 mg
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml
Nilotinib	Cap 150 mg
Nilotinib	Cap 200 mg
Nimodipine	Inj 0.2 mg per ml
Omeprazole	Inj 40 mg ampoule with diluent
Oxytocin	Inj 5 iu per ml
Oxytocin	Inj 10 iu per ml
Oxytocin with ergometrine	Inj 5 iu with ergometrine maleate 500 mcg per ml
Perindopril with amlodipine	Tab perindopril arginine 10 mg with amlodipine 10 mg
Perindopril with amlodipine	Tab perindopril arginine 10 mg with amlodipine 5 mg

Chemical Name	Line Item
Perindopril with amlodipine	Tab perindopril arginine 5 mg with amlodipine 10 mg
Perindopril with amlodipine	Tab perindopril arginine 5 mg with amlodipine 5 mg
Pirfenidone (current access)	Tab 267 mg
Pirfenidone (current access)	Tab 801 mg
Pirfenidone (widened access)	Tab 267 mg
Pirfenidone (widened access)	Tab 801 mg
Plerixafor	Inj 20 mg per ml
Posaconazole	Oral liq 40 mg per ml
Raltegravir potassium	Tab 400 mg
Raltegravir potassium	Tab 600 mg
Sodium cromoglicate	Eye drops 2%
Sodium hyaluronate [hyaluronic acid]	Inj 5-10 mg/ml syringe
Sodium hyaluronate [hyaluronic acid]	Inj 11-15 mg/ml syringe
Sodium hyaluronate [hyaluronic acid]	Inj 16-20 mg/ml syringe
Sodium hyaluronate [hyaluronic acid]	Inj 21-25 mg/ml syringe
Sodium hyaluronate [hyaluronic acid]	Inj 26-30 mg/ml syringe
Sodium Hypochlorite	Soln 5%, 1,000-2,500 ml
Sumatriptan	Inj 12 mg per ml, 0.5 ml
Sunscreens, proprietary	SPF 50+ or greater
Telmisartan	Tab 40 mg
Telmisartan	Tab 80 mg
Telmisartan with amlodipine	Tab 40 mg with amlodipine 10 mg
Telmisartan with amlodipine	Tab 40 mg with amlodipine 5 mg
Telmisartan with amlodipine	Tab 80 mg with amlodipine 10 mg
Telmisartan with amlodipine	Tab 80 mg with amlodipine 5 mg
Teriparatide (current access)	Inj 250 mcg per ml
Teriparatide (widened access)	Inj 250 mcg per ml

The following items that were included in consultation have been removed from the 2024/25 ITT:

Chemical Name	Line Item
Cladribine	Tab 10 mg
Desogestrel	Tab 75 mcg
Everolimus	Tab 5 mg

Chemical Name	Line Item
Everolimus	Tab 10 mg
Nintedanib	Cap 100 mg
Nintedanib	Cap 150 mg

Additional Notes

Appropriate pack-size and packaging type

Where possible, Pharmac has identified Tender Items where there is a specific product preference in Schedule Two of the 2024/25 ITT document. For example (highlighted in red):

Dimethicone						
<u>Crm 5% (pack size 100 g or less)</u>				H	5%	Preference for a tube pack.
<u>Lozin - head lice suffocant</u>	7,487,000	\$159,099	\$0.0213	C H	5%	Preference for a pump bottle.
<u>Crm 5% (pack size greater than 100 g)</u>	6,278,500	\$53,995	\$0.0086	C H	5%	Preference for a pump bottle.

While Pharmac has taken all reasonable care in identifying these preferences, it makes no representation as to the accuracy of this information and accepts no liability for any errors or omissions. Suppliers should always undertake their own due diligence before submitting any tender bids.

Please note: we have historically indicated a preference for the pack size of Tender Items supplied in the community to be either a 30-day or 90-day pack. This improves dispensing efficiency and reduces wastage. We will be putting greater emphasis on packaging type and pack size in the future. There is a preference for bottle packs for tablets and capsules, where possible.

In this Tender we have identified specific packaging preferences for individual products in Schedule 2. We are aiming to expand this to a much wider range of products in future Tenders.

Oncology injectables

Health NZ hospitals are increasingly delivering chemotherapy treatment in satellite centers. These centers require compounded products to have a shelf-life greater than 24 hours. This accounts for delays in treatment transport and delivery. Therefore, Pharmac has indicated a preference for products with post-compounding stability data that is greater than 48 hours.

Ophthalmology Products (BAK-free)

Pharmac reserves its right to list a benzalkonium chloride (BAK) or preservative-free product for a restricted market. This is indicated in Schedule Two of the 2024/25 ITT. However, where a tender product is BAK-free it would have the entire market.

Access criteria

Pharmac is tendering for current or widened access for some products. This is indicated in Schedule Two of the 2024/25 ITT document. Links to clinical advice for these products have been included below. These detail the potential access criteria. Please note any access criteria are indicative only. Pharmac reserves the right to amend these criteria.

Chemical Name	Line Item(s)
Methylphenidate hydrochloride	Cap modified-release 10 mg Cap modified-release 20 mg Cap modified-release 30 mg Cap modified-release 40 mg Cap modified-release 60 mg

Chemical Name	Line Item(s)
Pirfenidone	Tab 267 mg Tab 801 mg
Teriparatide	Inj 250 mcg per ml
Varenicline	Tab 0.5 mg x 11 and 1 mg x 42 Tab 1 mg

Data estimates for PCT injectable products included in the 2024/25 ITT

All usage figures are in mg, rounded to the nearest 100 mg, for the period between 1 January 2023 to 31 December 2023. For each chemical, the table shows:

- The number of vials purchased directly by Health NZ hospitals, and
- The total number of mg supplied through third party facilities. Note that this will also contribute to the total demand for vials listed in the Schedule.

Usage data for PCT injectable products

Chemical Name	Presentation	Total usage
Bortezomib	Inj 3.5 mg vial	4,900 mg (1,403 vials)
	Compounding usage	33,500 mg
Carmustine	Inj 100 mg vial	8,600 mg (86 vials)
	Compounding usage	40,600 mg
Fludabarine phosphate	Inj 50 mg vial	9,200 mg (184 vials)
	Compounding usage	41,900 mg
Mitomycin C	Inj 5 mg vial	740 mg (148 vials)
	Inj 20 mg vial	500 mg (25 vials)
	Compounding usage	3,700 mg

Pharmac makes no representation as to the accuracy of this information or as to the level of sales or likely sales. While Pharmac has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information.

To be fair to all suppliers, we are unlikely to provide any further data relating to tender items while the 2024/25 ITT remains open.

More information

If you have any queries regarding the tender or require any assistance with the e-portal please contact the Tender Analysts (Imani Kerr and Sabrina Swerdloff) at tender@pharmac.govt.nz